Lexaria Bioscience (LEXX) Shares Outstanding (Weighted Average) (2010 - 2026)

Lexaria Bioscience has disclosed Shares Outstanding (Weighted Average) across 17 years of filings, most recently posting $11.1 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $11.1 million, up 46.69% year-over-year; the trailing twelve-month figure through Feb 2026 was $11.1 million (up 46.69% YoY), and the FY2025 annual result was $7.3 million, up 23.04% from the prior year.
• Shares Outstanding (Weighted Average) came in at $11.1 million for Q1 2026 at Lexaria Bioscience, up from $10.1 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $11.1 million in Q1 2026 to a low of $2.4 million in Q4 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $5.9 million (2024), against an average of $6.0 million.
• Across the five-year window, Shares Outstanding (Weighted Average) surged 274.88% in 2023 and sank 67.37% in 2024, its largest moves.
• Lexaria Bioscience's Shares Outstanding (Weighted Average) stood at $2.4 million in 2022, then soared by 274.88% to $9.1 million in 2023, then tumbled by 67.37% to $3.0 million in 2024, then jumped by 240.51% to $10.1 million in 2025, then grew by 10.29% to $11.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $11.1 million (Q1 2026), $10.1 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.